Duloxetine Hydrochloride
Product Images NDC 50436-0018

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Duloxetine Hydrochloride (NDC 50436-0018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

Kaplan-Meier plot showing the cumulative proportion of patients with relapse over time from randomization (days) in a study of Duloxetine versus placebo. The y-axis represents the proportion of patients with relapse, ranging from 0 to 1, while the x-axis shows time in days, up to 250. The graph compares Duloxetine-treated patients with placebo-treated patients, with the Duloxetine curve below the placebo curve, indicating fewer relapses over time.*

FDA Label Image

Figure-2 (Duloxetine Fig2)

A Kaplan-Meier curve chart showing the proportion of patients with relapse over time from randomization to relapse (days). The chart compares two treatment groups, Duloxetine (solid line) and Placebo (dashed line), illustrating relapse rates over approximately 280 days.*

FDA Label Image

Figure 3: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-1)

A line graph depicting the percentage of patients achieving various levels of pain relief measured by 24-hour average pain severity. The x-axis shows percent improvement in pain from baseline (0% to 100%), and the y-axis shows the percentage of patients improved (0% to 100%). Four lines compare Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 60 mg QD from another series, and placebo.*

FDA Label Image

Figure 4: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-2)

A line graph depicting the percentage of patients achieving various levels of pain relief measured by 24-hour average pain severity. The x-axis represents percent improvement in pain from baseline, ranging from greater than 0% to 100%. The y-axis shows the percentage of patients improved, ranging from 0% to 100%. Three lines are shown: Duloxetine 60 mg twice daily (B ID), Duloxetine 60 mg once daily (QD), and Placebo. The graph illustrates higher improvement percentages for both Duloxetine dosing regimens compared to placebo across pain improvement levels.*

FDA Label Image

Figure 7: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-1 (Duloxetine Fig5)

A line graph titled 'Figure 7: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-1.' The graph compares placebo and Duloxetine (60 mg/120 mg once daily) treatments, showing the percentage of patients improved across different percent improvement levels in pain from baseline (BOCF). Duloxetine shows higher percentages of improvement compared to placebo across most levels.*

FDA Label Image

Figure 8: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-3 (Duloxetine Fig6)

A line graph comparing the percentage of patients achieving various levels of pain relief from baseline between Duloxetine 60 mg once daily and placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. The Duloxetine line consistently plots higher than placebo across increasing pain relief levels from >0% to 100%.*

FDA Label Image

Figure 9: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Oa-1 (Duloxetine Fig7)

A line graph titled 'Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity.' It shows percentage of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. Two data lines compare placebo and Duloxetine (60 mg/120 mg once daily), displaying higher pain relief percentages for Duloxetine across all improvement levels.*

FDA Label Image

Structure (Duloxetine Str)

Chemical structure of duloxetine presented as a two-dimensional molecular diagram showing its atomic connections and configuration, including a naphthalene ring, sulfur heterocycle, and amine hydrochloride group.*

FDA Label Image

Label Image (Lbl504360018)

Duloxetine Hydrochloride delayed-release capsules 30 mg, 60 count carton label. Distributed by Citron Pharma LLC, East Brunswick, NJ. Manufactured with NDC 50436-0018-2. Label mentions unit dose packaging by Unit Dose Services, LLC, Panama, FL. Clear RX only designation with storage instructions to keep at 20-25°C in a controlled room temperature.*

FDA Label Image

Label Image (Lbl504360019)

Duloxetine Hydrochloride delayed-release capsules, 60 mg strength, 30 count unit dose packaging. The label includes NDC 50436-0019-1, manufacturing and distribution details for Citron Pharma LLC, and Unit Dose Services as the packager. It features warnings, lot and expiration placeholders, and administration instructions for oral use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.